Vavricka John 4
4 · Atea Pharmaceuticals, Inc. · Filed Feb 1, 2021
Insider Transaction Report
Form 4
Vavricka John
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-01-29+117,300→ 117,300 totalExercise: $73.00Exp: 2031-01-28→ Common Stock (117,300 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021.